Placebo News and Research

RSS

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

Pfizer Inc. today announced detailed overall survival data from the PALOMA-3 trial, which evaluated IBRANCE (palbociclib) in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer whose disease progressed on or after prior endocrine therapy.

22 Oct 2018

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., today announced detailed results from the Phase III SOLO-1 trial testing LYNPARZA (olaparib) 300 mg tablets twice-daily as a maintenance treatment for patients with newly diagnosed advanced BRCA-mutated ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy.

22 Oct 2018

Immunotherapy increases survival in some patients with metastatic triple negative breast cancer

Immunotherapy improves survival in some patients with metastatic triple negative breast cancer, according to late-breaking results from the IMpassion130 trial reported at the ESMO 2018 Congress in Munich.

22 Oct 2018

Phase III trial reports positive results with HDAC inhibitor in advanced breast cancer patients

Epigenetic therapy with histone deacetylase inhibitors is worth pursuing in hormone receptor positive advanced breast cancer, suggests a phase III trial reported today at the ESMO 2018 Congress in Munich.

22 Oct 2018

Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients

A high concentration of multi-strain probiotic helps to reduce mild to moderate episodes of chemotherapy-induced diarrhea in cancer patients, according to results of a phase II/III study in India.

22 Oct 2018

Immune therapy may be potential treatment option for patients with hard-to-treat ankylosing spondylitis

Results from a phase 3 clinical trial indicate that patients who have not benefited from standard therapy for ankylosing spondylitis, a chronic inflammatory disease characterized by back pain and sacroiliac-joint damage, may have another treatment option in the biologic drug ixekizumab.

22 Oct 2018

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Gilead Sciences, Inc. and Galapagos NV today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents.

22 Oct 2018

Breast cancer survival could be extended with two new drug combinations

A new study has shown that a combination of drugs palbociclib, along with hormone therapy can significantly increase the survival among women with advanced breast cancer.

21 Oct 2018

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

HealthCore, Inc., the outcomes research subsidiary of Anthem, Inc. and Novo Nordisk Inc., which manufacturers the once weekly GLP-1 receptor agonist Ozempic (semaglutide), are working together to launch the first of its kind pragmatic study to understand the benefits of semaglutide as compared with all other available diabetes drugs in a real-world pragmatic clinical trial for Type 2 diabetes - one of the nation's fastest growing chronic diseases.

17 Oct 2018

Purdue Pharma, Eisai announce positive topline results from Phase 3 study of lemborexant

Eisai Co., Ltd. and Purdue Pharma L.P. announced positive topline results from SUNRISE 2, a long-term Phase 3 efficacy and safety evaluation of lemborexant, an investigational agent for sleep-wake regulation currently being studied for the potential treatment of multiple sleep-wake disorders.

17 Oct 2018

Eisai enters into agreement with Eurofarma for development and sales of lorcaserin in 17 countries

Eisai Co., Ltd. has entered into an agreement to grant exclusive development and marketing rights for its anti-obesity agent lorcaserin hydrochloride (generic name, product name in the United States: BELVIQ, product name for once-daily formulation in the United States: BELVIQ XR, "lorcaserin") in 17 countries in Latin America and the Caribbean, excluding Brazil, to Eurofarma Laboratorios S.A. which has a business foundation in Latin America.

16 Oct 2018

Researchers develop fibrin-targeting immunotherapy to protect against neurodegeneration

Normally, the blood protein fibrin does not enter the brain. But in several neurological disorders, the blood-brain barrier--which keeps large molecules in the blood from entering the brain--becomes abnormally permeable, allowing fibrin to leak into the brain and trigger inflammation.

16 Oct 2018

Study shows no added benefit of pertuzumab combination in treatment of early breast cancer

For the third time since 2013, the German Institute for Quality and Efficiency in Health Care (IQWiG) examined in an early benefit assessment the added benefit of the drug pertuzumab in the treatment of HER2-positive breast cancer.

12 Oct 2018

Researchers identify effective ketamine dosage levels for patients with treatment-resistant depression

A study led by Massachusetts General Hospital investigators identifies two subanesthetic dosage levels of the anesthetic drug ketamine that appear to provide significant symptom relief to patients with treatment-resistant depression.

11 Oct 2018

Chewing gum could be a strategy to help reduce vitamin deficiency

Nearly 15 percent of all chewing gum varieties sold promise to provide health-enhancing supplements to users, so Penn State researchers studied whether two vitamin-supplemented products were effective at delivering vitamins to the body. Their results validate the concept of gum as an effective delivery system for at least some vitamins.

10 Oct 2018

Researchers create open access database on healthy immunity

Researchers have created a freely available database of healthy human immunity that can serve as an instant comparison group in immune system studies.

9 Oct 2018

FDA and EMA accept Novartis' regulatory application for siponimod to treat SPMS in adults

Novartis today announced that both the US Food and Drug Administration and European Medicines Agency have accepted the company's New Drug Application and Marketing Authorization Application respectively, for investigational oral, once-daily siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis in adults.

8 Oct 2018

Diet and weight may influence response to bipolar disorder treatment, shows study

Data from a clinical trial has shown that how people respond to treatment for Bipolar Disorder may be influenced by their weight and the overall quality of their diet, including whether they are eating a diet high in foods thought to contribute to general inflammation.

8 Oct 2018

T-CALM Phase 2 clinical study results offer hope for essential tremor patients

Cavion, Inc., a leading clinical stage biotechnology company committed to developing novel therapeutics for people with neurological diseases, today announced promising results of the T-CALM Phase 2 clinical trial of its first-in-class T-type calcium channel modulator CX-8998 in essential tremor.

7 Oct 2018

Lilly, Boehringer Ingelheim present full results of cardiovascular outcome trial, CARMELINA

Boehringer Ingelheim and Eli Lilly and Company today presented the full results of the long-term cardiovascular outcome trial, CARMELINA®, which studied the impact of Trajenta® (linagliptin) on cardiovascular and kidney safety in adults with type 2 diabetes at high risk for heart and/or kidney disease.

5 Oct 2018

Placebo News and Research

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

Immunotherapy increases survival in some patients with metastatic triple negative breast cancer

Phase III trial reports positive results with HDAC inhibitor in advanced breast cancer patients

Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients

Immune therapy may be potential treatment option for patients with hard-to-treat ankylosing spondylitis

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Breast cancer survival could be extended with two new drug combinations

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

Purdue Pharma, Eisai announce positive topline results from Phase 3 study of lemborexant

Eisai enters into agreement with Eurofarma for development and sales of lorcaserin in 17 countries

Researchers develop fibrin-targeting immunotherapy to protect against neurodegeneration

Study shows no added benefit of pertuzumab combination in treatment of early breast cancer

Researchers identify effective ketamine dosage levels for patients with treatment-resistant depression

Chewing gum could be a strategy to help reduce vitamin deficiency

Researchers create open access database on healthy immunity

FDA and EMA accept Novartis' regulatory application for siponimod to treat SPMS in adults

Diet and weight may influence response to bipolar disorder treatment, shows study

T-CALM Phase 2 clinical study results offer hope for essential tremor patients

Lilly, Boehringer Ingelheim present full results of cardiovascular outcome trial, CARMELINA

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News